Atom Investors LP Invests $4.14 Million in Fractyl Health, Inc. $GUTS

Atom Investors LP bought a new position in Fractyl Health, Inc. (NASDAQ:GUTS) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 1,883,018 shares of the company’s stock, valued at approximately $4,143,000. Atom Investors LP owned approximately 1.37% of Fractyl Health at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Rosalind Advisors Inc. acquired a new position in shares of Fractyl Health in the 3rd quarter worth approximately $7,950,000. CM Management LLC acquired a new position in shares of Fractyl Health in the 3rd quarter worth approximately $954,000. Osaic Holdings Inc. grew its position in shares of Fractyl Health by 460.3% in the 2nd quarter. Osaic Holdings Inc. now owns 59,645 shares of the company’s stock worth $97,000 after acquiring an additional 49,000 shares in the last quarter. Commonwealth Equity Services LLC acquired a new position in shares of Fractyl Health in the 4th quarter worth approximately $85,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Fractyl Health in the 3rd quarter worth approximately $81,000.

Fractyl Health Trading Down 8.7%

NASDAQ:GUTS opened at $0.78 on Wednesday. Fractyl Health, Inc. has a 12-month low of $0.38 and a 12-month high of $2.45. The firm has a market capitalization of $123.11 million, a P/E ratio of -0.60 and a beta of 2.34. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28. The business has a 50 day simple moving average of $0.71 and a 200 day simple moving average of $1.06.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.23. Equities research analysts predict that Fractyl Health, Inc. will post -0.6 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Fractyl Health in a research report on Tuesday, May 12th. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a research report on Thursday, June 4th. Wall Street Zen upgraded Fractyl Health from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a research report on Thursday, March 26th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $5.40.

Insider Buying and Selling

In related news, Director Ian Sheffield acquired 35,000 shares of Fractyl Health stock in a transaction that occurred on Wednesday, June 10th. The stock was acquired at an average price of $0.73 per share, for a total transaction of $25,550.00. Following the transaction, the director directly owned 35,000 shares of the company’s stock, valued at $25,550. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director William Bradley acquired 68,493 shares of Fractyl Health stock in a transaction that occurred on Wednesday, June 10th. The shares were bought at an average price of $0.73 per share, with a total value of $49,999.89. Following the transaction, the director directly owned 84,622 shares in the company, valued at approximately $61,774.06. This trade represents a 424.66% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 171,493 shares of company stock valued at $127,150 in the last 90 days. Insiders own 8.52% of the company’s stock.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.